BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 208 filers reported holding BRIDGEBIO PHARMA INC in Q2 2021. The put-call ratio across all filers is 1.95 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,593,235 | +159.9% | 1,160,153 | +69.5% | 0.01% | +166.7% |
| Q2 2023 | $11,772,866 | +1232.0% | 684,469 | +1184.0% | 0.00% | – |
| Q1 2023 | $883,846 | +172.1% | 53,308 | +25.1% | 0.00% | – |
| Q4 2022 | $324,818 | -89.8% | 42,627 | -86.6% | 0.00% | -100.0% |
| Q3 2022 | $3,170,000 | +708.7% | 318,882 | +638.0% | 0.00% | – |
| Q2 2022 | $392,000 | -12.7% | 43,209 | -2.2% | 0.00% | – |
| Q1 2022 | $449,000 | -43.7% | 44,190 | -7.6% | 0.00% | – |
| Q4 2021 | $798,000 | -67.8% | 47,839 | -9.5% | 0.00% | -100.0% |
| Q3 2021 | $2,478,000 | -12.9% | 52,866 | +13.3% | 0.00% | 0.0% |
| Q2 2021 | $2,845,000 | +88.8% | 46,659 | +90.6% | 0.00% | – |
| Q1 2021 | $1,507,000 | -42.0% | 24,474 | -33.0% | 0.00% | -100.0% |
| Q4 2020 | $2,598,000 | +1070.3% | 36,532 | +519.1% | 0.00% | – |
| Q3 2020 | $222,000 | -21.8% | 5,901 | -39.7% | 0.00% | – |
| Q1 2020 | $284,000 | +18.3% | 9,792 | +42.9% | 0.00% | – |
| Q4 2019 | $240,000 | – | 6,851 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $55,099,000 | 39.31% |
| M28 Capital Management LP | 466,200 | $4,233,000 | 4.74% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $282,034,000 | 3.75% |
| Octagon Capital Advisors LP | 933,743 | $8,478,000 | 2.26% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $241,719,000 | 1.11% |
| HHLR ADVISORS, LTD. | 5,362,014 | $48,687,000 | 1.04% |
| Cormorant Asset Management, LP | 1,469,179 | $13,340,000 | 1.01% |
| Knott David M Jr | 213,206 | $1,936,000 | 0.81% |
| Fernwood Investment Management, LLC | 183,900 | $1,670,000 | 0.72% |
| HighVista Strategies LLC | 105,942 | $962,000 | 0.58% |